Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Recurrence of progressive skin involvement following discontinuation or dose reduction of Mycophenolate Mofetil treatment in patients with diffuse Systemic Sclerosis.

Mendoza FA, Lee-Ching C, Jimenez SA.

Semin Arthritis Rheum. 2019 Jun 19. pii: S0049-0172(19)30084-8. doi: 10.1016/j.semarthrit.2019.06.012. [Epub ahead of print]

PMID:
31311679
2.

Abrogation of transforming growth factor-β-induced tissue fibrosis in mice with a global genetic deletion of Nox4.

Wermuth PJ, Mendoza FA, Jimenez SA.

Lab Invest. 2019 Apr;99(4):470-482. doi: 10.1038/s41374-018-0161-1. Epub 2018 Nov 23.

3.

Characteristics of Chronic Itch in Systemic Sclerosis: A Cross-sectional Survey.

Stull CM, Weaver LA, Valdes-Rodriguez R, Naramala S, Lavery MJ, Chan YH, Mendoza FA, Yosipovitch G.

Acta Derm Venereol. 2018 Aug 29;98(8):793-794. doi: 10.2340/00015555-2966. No abstract available.

4.

Collaborative eHealth Meets Security: Privacy-Enhancing Patient Profile Management.

Sanchez-Guerrero R, Mendoza FA, Diaz-Sanchez D, Cabarcos PA, Lopez AM.

IEEE J Biomed Health Inform. 2017 Nov;21(6):1741-1749. doi: 10.1109/JBHI.2017.2655419. Epub 2017 Aug 7.

PMID:
28796625
5.

Prediction of canned black bean texture (Phaseolus vulgaris L.) from intact dry seeds using visible/near infrared spectroscopy and hyperspectral imaging data.

Mendoza FA, Cichy KA, Sprague C, Goffnett A, Lu R, Kelly JD.

J Sci Food Agric. 2018 Jan;98(1):283-290. doi: 10.1002/jsfa.8469. Epub 2017 Sep 1.

PMID:
28585253
6.

Endothelial cell-specific activation of transforming growth factor-β signaling in mice induces cutaneous, visceral, and microvascular fibrosis.

Wermuth PJ, Carney KR, Mendoza FA, Piera-Velazquez S, Jimenez SA.

Lab Invest. 2017 Jul;97(7):806-818. doi: 10.1038/labinvest.2017.23. Epub 2017 Mar 27.

7.

Treatment of Rapidly Progressive Systemic Sclerosis: Current and Futures Perspectives.

Mendoza FA, Mansoor M, Jimenez SA.

Expert Opin Orphan Drugs. 2016;4(1):31-47. Epub 2015 Nov 23.

8.

Stimulation of Transforming Growth Factor-β1-Induced Endothelial-To-Mesenchymal Transition and Tissue Fibrosis by Endothelin-1 (ET-1): A Novel Profibrotic Effect of ET-1.

Wermuth PJ, Li Z, Mendoza FA, Jimenez SA.

PLoS One. 2016 Sep 1;11(9):e0161988. doi: 10.1371/journal.pone.0161988. eCollection 2016.

9.

Endothelial to Mesenchymal Transition (EndoMT) in the Pathogenesis of Human Fibrotic Diseases.

Piera-Velazquez S, Mendoza FA, Jimenez SA.

J Clin Med. 2016 Apr 11;5(4). pii: E45. doi: 10.3390/jcm5040045. Review.

10.

Severe eosinophilic fasciitis: comparison of treatment with D-penicillamine plus corticosteroids vs. corticosteroids alone.

Mendoza FA, Bai R, Kebede AG, Jimenez SA.

Scand J Rheumatol. 2016;45(2):129-34. doi: 10.3109/03009742.2015.1067713. Epub 2015 Nov 3.

11.

Endothelial Cells Expressing Endothelial and Mesenchymal Cell Gene Products in Lung Tissue From Patients With Systemic Sclerosis-Associated Interstitial Lung Disease.

Mendoza FA, Piera-Velazquez S, Farber JL, Feghali-Bostwick C, Jiménez SA.

Arthritis Rheumatol. 2016 Jan;68(1):210-7. doi: 10.1002/art.39421.

12.

Genetic diversity and genome-wide association analysis of cooking time in dry bean (Phaseolus vulgaris L.).

Cichy KA, Wiesinger JA, Mendoza FA.

Theor Appl Genet. 2015 Aug;128(8):1555-67. doi: 10.1007/s00122-015-2531-z. Epub 2015 May 24.

PMID:
26003191
13.

Strategies for anti-fibrotic therapies.

Rosenbloom J, Mendoza FA, Jimenez SA.

Biochim Biophys Acta. 2013 Jul;1832(7):1088-103. doi: 10.1016/j.bbadis.2012.12.007. Epub 2012 Dec 21. Review.

14.

Severe eosinophilic syndrome associated with the use of probiotic supplements: a new entity?

Mendoza FA, Purohit S, Kenyon L, Jimenez SA.

Case Rep Rheumatol. 2012;2012:934324. doi: 10.1155/2012/934324. Epub 2012 Dec 6.

15.

A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset.

Mendoza FA, Nagle SJ, Lee JB, Jimenez SA.

J Rheumatol. 2012 Jun;39(6):1241-7. doi: 10.3899/jrheum.111229. Epub 2012 Apr 1.

PMID:
22467932
16.

Systemic sclerosis disease modification clinical trials design: quo vadis?

Mendoza FA, Keyes-Elstein LL, Jimenez SA.

Arthritis Care Res (Hoboken). 2012 Jul;64(7):945-54. doi: 10.1002/acr.21667. No abstract available.

17.

Tyrosine kinase inhibitor therapy for systemic sclerosis: Quo Vadis?

Mendoza FA, Jiménez SA.

Arthritis Rheum. 2011 Nov;63(11):3199-203. doi: 10.1002/art.30545. No abstract available.

18.

Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature.

Mendoza FA, Artlett CM, Sandorfi N, Latinis K, Piera-Velazquez S, Jimenez SA.

Semin Arthritis Rheum. 2006 Feb;35(4):238-49. Review.

Supplemental Content

Loading ...
Support Center